Published in J Virol on December 01, 1992
The IFITM proteins inhibit HIV-1 infection. J Virol (2010) 2.80
Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A (2013) 2.75
The interferon response inhibits HIV particle production by induction of TRIM22. PLoS Pathog (2008) 2.06
Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells. J Virol (2010) 1.69
Alpha interferon enhances TRIM5alpha-mediated antiviral activities in human and rhesus monkey cells. J Virol (2007) 1.49
Early control of H5N1 influenza virus replication by the type I interferon response in mice. J Virol (2009) 1.24
Partial inhibition of human immunodeficiency virus replication by type I interferons: impact of cell-to-cell viral transfer. J Virol (2009) 1.21
TLR2 and TLR4 triggering exerts contrasting effects with regard to HIV-1 infection of human dendritic cells and subsequent virus transfer to CD4+ T cells. Retrovirology (2009) 1.06
Regulation of human immunodeficiency virus replication by 2',5'-oligoadenylate-dependent RNase L. J Virol (1998) 1.02
Induction of CD4 expression and human immunodeficiency virus type 1 replication by mutants of the interferon-inducible protein kinase PKR. J Virol (1997) 0.91
IFI44 suppresses HIV-1 LTR promoter activity and facilitates its latency. Virology (2015) 0.84
Transfer of human CD4(+) T lymphocytes producing beta interferon in Hu-PBL-SCID mice controls human immunodeficiency virus infection. J Virol (1999) 0.83
A variant macaque-tropic human immunodeficiency virus type 1 is resistant to alpha interferon-induced restriction in pig-tailed macaque CD4+ T cells. J Virol (2013) 0.82
90K, an interferon-stimulated gene product, reduces the infectivity of HIV-1. Retrovirology (2013) 0.82
Low autocrine interferon beta production as a gene therapy approach for AIDS: Infusion of interferon beta-engineered lymphocytes in macaques chronically infected with SIVmac251. Retrovirology (2004) 0.78
IFN-dependent and -independent reduction in West Nile virus infectivity in human dermal fibroblasts. Viruses (2014) 0.76
Exogenous interferon prolongs survival of rabies infected mice. Virusdisease (2015) 0.75
Effect of type-I interferon on retroviruses. Viruses (2009) 0.75
Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. Proc Natl Acad Sci U S A (1988) 6.33
Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology (1991) 4.45
Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. Science (1989) 3.43
The interferons. Mechanisms of action and clinical applications. JAMA (1991) 2.68
Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection. AIDS Res Hum Retroviruses (1991) 2.29
Acid-labile human leukocyte interferon in homosexual men with Kaposi's sarcoma and lymphadenopathy. J Infect Dis (1982) 1.98
Alpha interferon inhibits early stages of the human immunodeficiency virus type 1 replication cycle. J Virol (1992) 1.94
Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann Intern Med (1990) 1.65
The natural history of human immunodeficiency virus infection. J Infect Dis (1988) 1.54
Regulation of HIV replication in infected monocytes by IFN-alpha. Mechanisms for viral restriction. J Immunol (1990) 1.44
Acid-labile alpha interferon. A possible preclinical marker for the acquired immunodeficiency syndrome in hemophilia. N Engl J Med (1983) 1.41
Immunological variables as predictors of prognosis in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome. Cancer Res (1986) 1.17
Inhibition of human immunodeficiency virus type 1 morphogenesis in T cells by alpha interferon. Antimicrob Agents Chemother (1991) 1.15
The role of interferons in the control of HIV replication in macrophages. Clin Immunol Immunopathol (1990) 1.14
Effect of interferon on murine leukaemia virus infection. IV. Formation of non-infectious virus in chronically infected cells. J Gen Virol (1979) 1.14
Alpha interferon suppresses virion but not soluble human immunodeficiency virus antigen production in chronically infected T-lymphocytic cells. J Virol (1991) 1.12
HIV antigen, HIV antibody and serum interferon in a patient with encephalopathy. Infection (1988) 1.05
Attenuation of HIV-1 infectivity by an inhibitor of oligosaccharide processing. AIDS Res Hum Retroviruses (1990) 0.98
Multiple effects of interferon on HIV-1 replication. J Interferon Res (1991) 0.96
Interferon-alpha treatment leads to accumulation of virus particles on the surface of cells persistently infected with the human immunodeficiency virus type 1. J Acquir Immune Defic Syndr (1990) 0.95
Interferon-treated cells release vesicular stomatitis virus particles lacking glycoprotein spikes: correlation with biochemical data. Proc Natl Acad Sci U S A (1980) 0.90
Effect of interferon treatment on vesicular stomatitis virus (VSV): release of unusual particles with low infectivity. Virology (1980) 0.89
Interferon inhibits C-type virus at a posttranscriptional, prerelease step. Arch Virol (1978) 0.88
Antiretroviral effect of interferon: proposed mechanism. J Interferon Res (1982) 0.87
Interferon alters intracellular transport of vesicular stomatitis virus glycoprotein. J Biol Regul Homeost Agents (1988) 0.86
The auto-regulation model: a unified concept of how HIV regulates its infectivity, pathogenesis and persistence. Int Rev Immunol (1992) 0.86
Interferon induces the production of membrane protein-deficient and infectivity-defective vesicular stomatitis virions through interference in the virion assembly process. J Gen Virol (1983) 0.83
Interferon-mediated inhibition of production of Gazdar murine sarcoma virus, a retrovirus lacking env proteins and containing an uncleaved gag precursor. Virology (1983) 0.82
Production of vesicular stomatitis virus with low infectivity by interferon-treated cells. J Gen Virol (1979) 0.82
Structural abnormalities in murine leukemia viruses produced by interferon-treated cells. Biochem Biophys Res Commun (1979) 0.82
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science (1994) 13.54
Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science (1986) 11.74
The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci U S A (1994) 7.85
Biological and biochemical characterization of a cloned Leu-3- cell surviving infection with the acquired immune deficiency syndrome retrovirus. J Exp Med (1986) 6.52
Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology (1992) 5.64
Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes. Proc Natl Acad Sci U S A (1991) 5.26
Trans-activation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses. Proc Natl Acad Sci U S A (1986) 4.89
Slow, persistent replication of lentiviruses: role of tissue macrophages and macrophage precursors in bone marrow. Proc Natl Acad Sci U S A (1985) 4.66
Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. J Immunol (1990) 4.36
The macrophage in the persistence and pathogenesis of HIV infection. AIDS (1989) 4.06
Live vaccine strain of Francisella tularensis: infection and immunity in mice. Infect Immun (1991) 3.99
Leishmania major amastigotes initiate the L-arginine-dependent killing mechanism in IFN-gamma-stimulated macrophages by induction of tumor necrosis factor-alpha. J Immunol (1990) 3.79
Mycobacterium avium-intracellulare: a cause of disseminated life-threatening infection in homosexuals and drug abusers. Ann Intern Med (1982) 3.58
Tropism of sheep lentiviruses for monocytes: susceptibility to infection and virus gene expression increase during maturation of monocytes to macrophages. J Virol (1986) 3.45
HIV requires multiple gp120 molecules for CD4-mediated infection. Nature (1990) 3.37
B cell stimulatory factor-1 (interleukin 4) activates macrophages for increased tumoricidal activity and expression of Ia antigens. J Immunol (1987) 3.18
Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother (1997) 2.98
Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci U S A (1992) 2.98
Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J Virol (1987) 2.84
Regulation of activated macrophage antimicrobial activities. Identification of lymphokines that cooperate with IFN-gamma for induction of resistance to infection. J Immunol (1988) 2.82
Selection of a fixative for identifying T cell subsets, B cells, and macrophages in paraffin-embedded mouse spleen. J Immunol Methods (1983) 2.82
Seminars in medicine of the Beth Israel Hospital, Boston. Dementia associated with the acquired immunodeficiency syndrome. N Engl J Med (1995) 2.73
Bidirectional amplification of macrophage-lymphocyte interactions: enhanced lymphocyte activation factor production by activated adherent mouse peritoneal cells. J Immunol (1977) 2.73
Role of mononuclear phagocytes in the pathogenesis of human immunodeficiency virus infection. Annu Rev Immunol (1990) 2.69
Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees. J Virol (1990) 2.65
Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants. J Virol (1992) 2.62
Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual. J Immunol (1990) 2.57
HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death Differ (2005) 2.54
Growth of Francisella tularensis LVS in macrophages: the acidic intracellular compartment provides essential iron required for growth. Infect Immun (1995) 2.52
Human immunodeficiency virus type 1 infection of the nervous system: pathogenetic mechanisms. Ann Neurol (1993) 2.49
Intracellular replication and lymphokine-induced destruction of Leishmania tropica in C3H/HeN mouse macrophages. J Immunol (1981) 2.39
Macrophages in resistance to rickettsial infection: macrophage activation in vitro for killing of Rickettsia tsutsugamushi. J Immunol (1979) 2.34
Cytokine-induced synthesis of nitrogen oxides in macrophages: a protective host response to Leishmania and other intracellular pathogens. J Leukoc Biol (1991) 2.30
Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses. J Virol (1987) 2.28
The role of the V3 loop of gp120 in HIV infection. AIDS (1991) 2.23
A model for monocyte migration through the blood-brain barrier during HIV-1 encephalitis. J Immunol (1997) 2.15
Macrophage activation for tumor cytotoxicity: development of macrophage cytotoxic activity requires completion of a sequence of short-lived intermediary reactions. J Immunol (1978) 2.12
Generation and characterization of a lipopolysaccharide-induced and serum-derived cytotoxic factor for tumor cells. Infect Immun (1980) 2.12
Regulation of nitric oxide synthase activity in human immunodeficiency virus type 1 (HIV-1)-infected monocytes: implications for HIV-associated neurological disease. J Exp Med (1995) 2.11
Human immunodeficiency virus type 1 infection alters chemokine beta peptide expression in human monocytes: implications for recruitment of leukocytes into brain and lymph nodes. Proc Natl Acad Sci U S A (1996) 2.02
Defective tumoricidal capacity of macrophages from C3H/HeJ mice. J Immunol (1978) 2.01
Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. J Virol (1992) 1.94
Macrophages in resistance to rickettsial infections: characterization of lymphokines that induce rickettsiacidal activity in macrophages. J Immunol (1981) 1.94
In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc Natl Acad Sci U S A (1994) 1.93
Enhanced HIV replication in macrophage colony-stimulating factor-treated monocytes. J Immunol (1991) 1.92
Immunohistochemical localization of human and simian immunodeficiency viral antigens in fixed tissue sections. Am J Pathol (1987) 1.92
Macrophage activation for tumor cytotoxicity: induction of tumoricidal macrophages by supernatants of PPD-stimulated Bacillus Calmette-Guérin-immune spleen cell cultures. J Immunol (1977) 1.91
Macrophages and the human immunodeficiency virus. Immunol Today (1990) 1.90
Inhibitory activity of interferons and interleukin 1 on the development of Plasmodium falciparum in human hepatocyte cultures. J Immunol (1987) 1.89
Microglial and astrocyte chemokines regulate monocyte migration through the blood-brain barrier in human immunodeficiency virus-1 encephalitis. Am J Pathol (1999) 1.86
Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain. J Immunol (1996) 1.83
Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J Immunol (1997) 1.77
Intracellular CXCR4 signaling, neuronal apoptosis and neuropathogenic mechanisms of HIV-1-associated dementia. J Neuroimmunol (1999) 1.76
Tumor cytotoxicity in vitro by macrophages from mice infected with mycobacterium bovis strain BCG. J Natl Cancer Inst (1974) 1.74
Life and death of an intracellular pathogen: Francisella tularensis and the macrophage. Immunol Ser (1994) 1.73
Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res Hum Retroviruses (1995) 1.72
Recombinant human gamma interferon inhibits simian malaria. Infect Immun (1986) 1.71
Macrophage proteomic fingerprinting predicts HIV-1-associated cognitive impairment. Neurology (2003) 1.70
Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies. J Virol (1993) 1.70
Neutralization of gamma interferon and tumor necrosis factor alpha blocks in vivo synthesis of nitrogen oxides from L-arginine and protection against Francisella tularensis infection in Mycobacterium bovis BCG-treated mice. Infect Immun (1993) 1.65
Macrophage-HIV interaction: viral isolation and target cell tropism. AIDS (1990) 1.64
Macrophage activation for tumor cytotoxicity: increased lymphokine responsiveness of peritoneal macrophages during acute inflammation. J Immunol (1978) 1.63
Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120. J Virol (1989) 1.61
Human immunodeficiency virus type 1 in spinal cords of acquired immunodeficiency syndrome patients with myelopathy: expression and replication in macrophages. Proc Natl Acad Sci U S A (1989) 1.61
A double labeling technique for performing immunocytochemistry and in situ hybridization in virus infected cell cultures and tissues. J Virol Methods (1985) 1.60
Serum containing tumor necrosis factor is cytotoxic for the human malaria parasite Plasmodium falciparum. Infect Immun (1983) 1.60
Tumoricidal responses in vitro of peritoneal macrophages from conventionally housed and germ-free nude mice. Cell Immunol (1976) 1.58
Nitric oxide-independent killing of Francisella tularensis by IFN-gamma-stimulated murine alveolar macrophages. J Immunol (1994) 1.57
Evolution of human immunodeficiency virus type 1 envelope sequences in infected individuals with differing disease progression profiles. Virology (1998) 1.57
Macrophage activation for tumor cytotoxicity: control of macrophage tumoricidal capacity by the LPS gene. J Immunol (1978) 1.56
Tumor regression after intralesional injection of emulsified trehalose-6,6'-dimycolate (cord factor): efficacy increases with oil concentration. Int J Cancer (1977) 1.56
Activation of the human immunodeficiency virus by herpes simplex virus type 1. J Virol (1987) 1.55
Evaluation of antiretroviral drug efficacy for HIV-1 encephalitis in SCID mice. Neurology (2000) 1.55
Human immunodeficiency virus encephalitis in SCID mice. Am J Pathol (1996) 1.55
A selective defect of interferon alpha production in human immunodeficiency virus-infected monocytes. J Exp Med (1990) 1.53
Light microscopic and ultrastructural evidence of in vivo phagocytosis of Helicobacter pylori by neutrophils. Ultrastruct Pathol (2001) 1.53
Thymosin beta4 accelerates wound healing. J Invest Dermatol (1999) 1.50
Defective tumoricidal capacity of macrophages from A/J mice. II. Comparison of the macrophage cytotoxic defect of A/J mice with that of lipid A-unresponsive C3H/HeJ mice. J Immunol (1979) 1.48
Efficiency of in situ hybridization as a function of probe size and fixation technique. J Virol Methods (1985) 1.47
Colony-stimulating factors. J Am Acad Dermatol (1990) 1.47
Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine. Proc Natl Acad Sci U S A (1987) 1.46
Genomic diversity and antigenic variation of HIV-1: links between pathogenesis, epidemiology and vaccine development. FASEB J (1991) 1.46
Tumor-specific antigen solubilized by hypertonic potassium chloride. J Natl Cancer Inst (1971) 1.46
Acceleration of viral replication and up-regulation of cytokine levels by antimalarials: implications in malaria-endemic areas. Am J Trop Med Hyg (1999) 1.45
Regulation of HIV replication in infected monocytes by IFN-alpha. Mechanisms for viral restriction. J Immunol (1990) 1.44
Metastatic meningioma. Hemangiopericytoma or angioblastic meningioma? Am J Surg Pathol (1993) 1.41
Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci (2007) 1.41
Blocking of human immunodeficiency virus infection depends on cell density and viral stock age. J Virol (1991) 1.40
Macrophage activation for tumor cytotoxicity: characterization of priming and trigger signals during lymphokine activation. J Immunol (1981) 1.40
Curcumin enhances wound healing in streptozotocin induced diabetic rats and genetically diabetic mice. Wound Repair Regen (1999) 1.40
Persistent expression of Ia antigen and viral genome in visna-maedi virus-induced inflammatory cells. Possible role of lentivirus-induced interferon. J Exp Med (1985) 1.39